Somatization and Sleep Quality on Patients with Comorbid Anxiety/Depression.

Background: Somatization is a common symptom among patients with comorbid anxiety and depression. It is associated with poorer outcome, long-term evolution, worse sleep patterns and an overall lower quality of life. Previous studies suggest that sleep disturbances exacerbate somatization, which in turn negatively affects sleep. The purpose of this study was to determine the correlation between anxiety/depression and somatization/sleep quality in hospitalized psychiatric patients. Methods:Participants comprised 103 hospitalized patients with somatic symptoms disorder as major diagnosis and anxiety and depression disorders as comorbid diagnoses. All subjects were given SOMS-2 and SOMS-7 (Screening for Somatoform Symptoms) for somatization symptoms, HAM-A (Hamilton Anxiety Rating Scale) for anxiety, HAM-D 17 (Hamilton Depression Rating Scale) for depression and PSQI (Pittsburgh Sleep Quality Index) for sleep quality. The Somatic Symptom Disorder-B criteria scale (SSD-12) has been also used for the psychological impact of somatization. The same scales were administered to a control group of 77 participants by trained physicians. Results:There was a negative correlation between the scores of HAM-A/HAM-D scales and those of SSD-12. Also, positive associations between the scores of anxiety and depression scales in patients with sleep disturbances were found. Sleep scores being assessed with PSQI were significantly higher after hospitalization in 80% of participants and did not correlate with neither anxiety/depression nor somatization. In the participant group, SOMS-2 results were not correlated with any social and demographic variables. All scales scores were worse in the study group than the control group. Conclusion:Anxiety and depression symptoms may be associated with higher somatization symptoms but not with the psychological impact of somatization. Also, somatization may not directly impact sleep quality scores. Further approaches are needed to better understand the relationship between sleep quality and somatization, on one hand, and its modulation by comorbid psychiatric disorders, on the other hand.

Association between Liver Cirrhosis and Diabetes Mellitus: A Review on Hepatic Outcomes.

BACKGROUND: Liver cirrhosis (LC) is largely associated with diabetes mellitus (DM). More than 80% of patients with LC manifest glucose intolerance and about 30% have type 2 DM. A particular and yet unrecognized entity is hepatogenous diabetes (HD), defined as impaired glucose regulation caused by altered liver function following LC. Numerous studies have shown that DM could negatively influence liver-related outcomes. AIM: We aimed to investigate whether patients with LC and DM are at higher risk for hepatic encephalopathy (HE), variceal hemorrhage (VH), infections and hepatocellular carcinoma (HCC). The impact of DM on liver transplant (LT) outcomes was also addressed. METHODS: Literature search was performed in PubMed, Ovid, and Elsevier databases. Population-based observational studies reporting liver outcomes in patients with LC were included. RESULTS: Diabetics are at higher risk for HE, including post-transjugular intrahepatic portosystemic shunt HE. DM also increases the risk of VH and contributes to elevated portal pressure and variceal re-bleeding, while uncontrolled DM is associated with increased risk of bacterial infections. DM also increases the risk of HCC and contributes to adverse LT outcomes. CONCLUSIONS: Patients with DM and LC may benefit from close follow-up in order to reduce readmissions and mortality. Due to the heterogeneity of available research, prospective multicenter clinical trials are needed to further validate these findings.

On the Dual Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) in Human Malignancies.

Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a glycoprotein belonging to the carcinoembryonic antigen (CEA) family that is expressed on a wide variety of cells and holds a complex role in inflammation through its alternate splicing and generation of various isoforms, mediating intricate mechanisms of modulation and dysregulation. Initially regarded as a tumor suppressor as its expression shows considerable downregulation within the epithelia in the early phases of many solid cancers, CEACAM1 has been linked lately to the progression of malignancy and metastatic spread as various papers point to its role in tumor progression, angiogenesis, and invasion. We reviewed the literature and discussed the various expression patterns of CEACAM1 in different types of tumors, describing its structure and general biologic functions and emphasizing the most significant findings that link this molecule to poor prognosis. The importance of understanding the role of CEACAM1 in cell transformation stands not only in this adhesion molecule's value as a prognostic factor but also in its promising premise as a potential new molecular target that could be exploited as a specific cancer therapy.